Effect of Acetazolamide Additional Therapy on Loop Diuretic for Achieving an Effective Treatment in Acute Heart Failure Patients: A Systematic Review
DOI:
https://doi.org/10.35790/msj.v6i1.52794Abstract
Abstract: Hospital readmissions are primarily caused by signs and symptoms of congestion of acute heart failure (AHF). Loop diuretics are commonly used to treat volume excess. It has been suggested by earlier studies in AHF patients that combination of loop diuretics with acetazolamide can increase the effectiveness of loop diuretics. This study aimed to obtain the impact of acetazolamide addition on loop diuretic therapy in AHF patients and assess the benefit of the combination. This was a systematic review using PubMed and ScienceDirect to retrieve data in 2013 and 2023, focusing on Randomized Controlled Trials (RCTs) involving AHF patients treated with both loop diuretics and acetazolamide. The results showed that 573 patients from a total of four RCTs were included in the study. Acetazolamide additional therapy helped loop diuretic to increase natriuresis (in all of the studies) and urine output (in two studies). The congestion symptoms also reduced in patients who received acetazolamide additional therapy on dose 500 mg intravenously within three days (p<0.05) in two studies. However, patients who received acetazolamide therapy also had an increase in serum creatinine levels in two studies. In conclusion, adding acetazolamide to loop diuretic therapy can increase the effectiveness of loop diuretics to achieve successful decongestion in AHF patients. Additionally, acetazolamide-treated individuals exhibit natriuresis and urin output higher than those in the control group, despite it also raises serum creatinin level.
Keywords: acetazolamide; loop diuretics; acute heart failure; decongestion
References
Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171(3):368-76. Doi: 10.1016/j.ijcard.2013.12.028.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC [published correction appears in Eur Heart J. 2016 Dec 30]. Eur Heart J. 2016;37(27):2129-200. Doi: 10.1093/eurheartj/ehw128
Fallahzadeh MA, Dormanesh B, Fallahzadeh MK, Roozbeh J, Fallahzadeh MH, Sagheb MM. Acetazolamide and hydrochlorothiazide followed by furosemide versus furosemide and hydrochlorothiazide followed by furosemide for the treatment of adults with nephrotic edema: a randomized trial [published correction appears in Am J Kidney Dis. 2017 Aug;70(2):305]. Am J Kidney Dis. 2017;69(3):420-7. Doi: 10.1053/j.ajkd.2016.10.022.
Zahedi K, Barone S, Xu J, Soleimani M. Potentiation of the effect of thiazide derivatives by carbonic anhydrase inhibitors: molecular mechanisms and potential clinical implications. PLoS One. 2013;8(11):e79327. Doi: 10.1371/journal.pone.0079327.
Imiela T, Budaj A. Acetazolamide as add-on diuretic therapy in exacerbations of chronic heart failure: a pilot study. Clin Drug Investig. 2017;37(12):1175-81. Doi: 10.1007/s40261-017-0577-1.
Verbrugge FH, Dupont M, Steels P, Grieten L, Swennen Q, Tang WH, et al. The kidney in congestive heart failure: 'are natriuresis, sodium, and diuretics really the good, the bad and the ugly?' Eur J Heart Fail. 2014;16(2):133-42. Doi: 10.1002/ejhf.35.
An Y, Zhang JZ, Han J, Yang HP, Tie L, Yang XY, et al. Hypoxia-inducible factor-1α dependent pathways mediate the renoprotective role of acetazolamide against renal ischemia-reperfusion injury. Cell Physiol Biochem. 2013;32(5):1151-66. Doi:10.1159/000354515.
Verbrugge FH, Martens P, Dauw J, Nijst P, Meekers E, Augusto SN Jr, et al. Natriuretic response to acetazolamide in patients with acute heart failure and volume overload. J Am Coll Cardiol. 2023;81(20):2013-24. Doi: 10.1016/j.jacc.2023.03.400.
Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377:1964–75. Doi: 10.1056/NEJMra1703100.
Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in acute decompensated heart failure with volume overload. New Engl J Med. 2022;387(13):1185-95. Doi: 10.1056/NEJMoa2203094.
Kassamali R, Sica DA. Acetazolamide: a forgotten diuretic agent. Cardiol Rev. 2011;19(6):276–8. Doi: 10.1097/CRD.0b013e31822b4939
Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M, et al. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. Eur J Heart Fail. 2019;21(11):1415-22. Doi: 10.1002/ejhf.1478.
Amlal H, Soleimani M. Pendrin as a novel target for diuretic therapy. Cell Physiol Biochem. 2011:28(3):521–6. Doi: 10.1159/000335117.
Verbrugge FH. Editor's Choice-Diuretic resistance in acute heart failure. Eur Heart J Acute Cardiovasc Care. 2018;7(4):379-89. Doi:10.1177/2048872618768488.
Verbrugge FH, Dupont M, Bertrand PB, Nijst P, Penders J, Dens J, et al. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. Acta Cardiol. 2015;70(3):265-73. Doi: 10.1080/ac.70.3.3080630.
Damman K, Tang WH, Testani JM, McMurray JJ. Terminology and defnition of changes renal function in heart failure. Eur Heart J. 2014;35(48):3413–6. Doi: 10.1093/eurheartj/ehu320
Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J. 2015;36(23):1437–44. Doi: 10.1093/eurheartj/ehv010.
Verbrugge FH, Martens P, Mullens W. SGLT-2 inhibitors in heart failure: implications for the kidneys. Curr Heart Fail Rep. 2017;14(4):331-7. Doi: 10.1007/s11897-017-0345-9.
Greene SJ, Gheorghiade M, Vaduganathan M, Ambrosy AP, Mentz RJ, Subacius H, et al. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail. 2013;15(12):1401-11. Doi:10.1093/eurjhf/hft110.
Verbrugge FH, Nijst P, Dupont M, Reynders C, Penders J, Tang WH, et al. Prognostic value of glomerular filtration changes versus natriuretic response in decompensated heart failure with reduced ejection. J Card Fail. 2014;20(11):817-24. Doi: 10.1016/j.cardfail.2014.08.002.
Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587-97. Doi: 10.1161/CIRCULATIONAHA.113.005081.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-34. Doi: 10.1056/NEJMoa1515920.
Neal B, Perkovic V, Mahaffey KW. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-57. Doi: 10.1056/NEJMoa16119.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Annisa T. Fadilla, Muhammad Sabri, Idham Junantaruna, Ajibaskoro P. Ibrahim
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
COPYRIGHT
Authors who publish with this journal agree to the following terms:
Authors hold their copyright and grant this journal the privilege of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that permits others to impart the work with an acknowledgment of the work's origin and initial publication by this journal.
Authors can enter into separate or additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (for example, post it to an institutional repository or publish it in a book), with an acknowledgment of its underlying publication in this journal.
Authors are permitted and encouraged to post their work online (for example, in institutional repositories or on their website) as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).
